Sino Biological has concluded the acquisition of Canadian biotechnology company SignalChem Biotech (SCB) for $48m in a move that expands its product portfolio and strengthens its global presence.

The related share purchase agreement was signed between the companies in October 2023.

The deal includes all assets and assumed indebtedness, along with net cash deposits, marking a significant expansion for the Shenzhen stock exchange-listed biotech company.

Sino Biological president and general manager Dr Jie Zhang stated: “SignalChem is at the scientific forefront of enzyme bioreagent development and production, as well as enzyme-based compound screening technologies.

“The acquisition of SCB further strengthens Sino Biological’s robust presence in bioactive recombinant proteins and related contract research services.”

SignalChem is engaged in developing bioactive enzymes, including kinases, proteases, phosphatases, ubiquitin and epigenetic enzymes.

 It is now integrated as a wholly-owned subsidiary of Sino Biological.

SCB will offer exclusive expertise in enzyme production to its existing technology platforms.

The merger of Sino Biological and SignalChem is expected to deliver a wider range of products and services to the life sciences community.

The strategic synergy aims to accelerate the discovery and development of new treatments, vaccines and diagnostic tools.

SignalChem Biotech co-founder, president and CEO Jun Yan said: “We are excited to join forces with Sino Biological and embark on this new chapter of growth and collaboration.

“Together, we have a unique opportunity to leverage our complementary strengths and resources to accelerate innovation and better serve the scientific community. We look forward to combining our expertise to develop novel solutions that address the complex challenges facing researchers around the world.”